| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurology (Y.L., R.G., R.D., A.R., M.A.-H., M.S.) and Nuclear Medicine (M.L.) and Epidemiology Unit (M.B.), Edith Wolfson Medical Center, Holon and Sackler Faculty of Medicine, Tel Aviv University, Israel.
Address correspondence and reprint requests to Dr. Y. Lampl, Department of Neurology, Edith Wolfson Medical Center, Holon 58100, Israel y_lampl{at}hotmail.com
Background: Ischemic animal model studies have shown a neuroprotective effect of minocycline.
Objective: To analyze the effect of minocycline treatment in human acute ischemic stroke.
Methods: We performed an open-label, evaluator-blinded study. Minocycline at a dosage of 200 mg was administered orally for 5 days. The therapeutic window of time was 6 to 24 hours after onset of stroke. Data from NIH Stroke Scale (NIHSS), modified Rankin Scale (mRS), and Barthel Index (BI) were evaluated. The primary objective was to compare changes from baseline to day 90 in NIHSS in the minocycline group vs placebo.
Results: One hundred fifty-two patients were included in the study. Seventy-four patients received minocycline treatment, and 77 received placebo. NIHSS and mRS were significantly lower and BI scores were significantly higher in minocycline-treated patients. This pattern was already apparent on day 7 and day 30 of follow-up. Deaths, myocardial infarctions, recurrent strokes, and hemorrhagic transformations during follow-up did not differ by treatment group.
Conclusions: Patients with acute stroke had significantly better outcome with minocycline treatment compared with placebo. The findings suggest a potential benefit of minocycline in acute ischemic stroke.
GLOSSARY: ACE = angiotensin-converting enzyme; ACEI = angiotensin-converting enzyme inhibitor; BI = Barthel Index; mRS = modified Rankin Scale; NIHSS = NIH Stroke Scale; PUD = peptic ulcer disease; SU = sulfonylurea.
Received May 2, 2006. Accepted in final form April 27, 2007.
Disclosure: The authors report no conflicts of interest.
This article has been cited by other articles:
|
|
 |
|
  G. N. Neigh, K. Karelina, E. R. Glasper, S. L.K. Bowers, N. Zhang, P. G. Popovich, and A. C. DeVries Anxiety After Cardiac Arrest/Cardiopulmonary Resuscitation: Exacerbated by Stress and Prevented by Minocycline Stroke, November 1, 2009; 40(11): 3601 - 3607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Hotchkiss, A. Strasser, J. E. McDunn, and P. E. Swanson Cell Death N. Engl. J. Med., October 15, 2009; 361(16): 1570 - 1583. [Full Text] [PDF]
|
|
|
|
 |
|
 D. van de Beek, E. F. M. Wijdicks, F. H. Vermeij, R. J. de Haan, J. M. Prins, L. Spanjaard, D. W. J. Dippel, and P. J. Nederkoorn Preventive Antibiotics for Infections in Acute Stroke: A Systematic Review and Meta-analysis Arch Neurol, September 1, 2009; 66(9): 1076 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Drabek, S. A. Tisherman, L. Beuke, J. Stezoski, K. Janesko-Feldman, M. Lahoud-Rahme, and P. M. Kochanek Deep Hypothermia Attenuates Microglial Proliferation Independent of Neuronal Death After Prolonged Cardiac Arrest in Rats Anesth. Analg., September 1, 2009; 109(3): 914 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vojdani and J. Lambert The Role of Th17 in Neuroimmune Disorders: Target for CAM Therapy. Part II Evid. Based Complement. Altern. Med., July 21, 2009; (2009) nep063v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vojdani, J. Lambert, and G. Kellermann The Role of Th17 in Neuroimmune Disorders: A Target for CAM Therapy. Part III Evid. Based Complement. Altern. Med., July 21, 2009; (2009) nep064v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Novakovic, G Toth, and P D Purdy Review of current and emerging therapies in acute ischemic stroke JNIS, July 1, 2009; 1(1): 13 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Optimising the Analysis of Stroke Trials (OAST Should Stroke Trials Adjust Functional Outcome for Baseline Prognostic Factors? Stroke, March 1, 2009; 40(3): 888 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Alberts, R. A. Felberg, L. R. Guterman, S. R. Levine, and for Writing Group 4 Atherosclerotic Peripheral Vascular Disease Symposium II: Stroke Intervention: State of the Art Circulation, December 16, 2008; 118(25): 2845 - 2851. [Full Text] [PDF]
|
|
|
|
 |
|
 W.-R Schabitz, A. Schneider, R. Laage, Y. Lampl, and M. Boaz MINOCYCLINE TREATMENT IN ACUTE STROKE: AN OPEN-LABEL, EVALUATOR-BLINDED STUDY Neurology, October 28, 2008; 71(18): 1461 - 1461. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Romero-Perez, E. Fricovsky, K. G. Yamasaki, M. Griffin, M. Barraza-Hidalgo, W. Dillmann, and F. Villarreal Cardiac Uptake of Minocycline and Mechanisms for In Vivo Cardioprotection J. Am. Coll. Cardiol., September 23, 2008; 52(13): 1086 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Orsucci, M. Mancuso, and G. Siciliano Mitochondria, oxidative stress and PARP-1 network: a new target for neuroprotective effects of tetracyclines? J. Physiol., May 15, 2008; 586(10): 2427 - 2428. [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Lee Can the Use of Oral Minocycline Improve Ischemic Stroke Outcomes? Journal of Pharmacy Practice, April 1, 2008; 21(2): 159 - 164. [Abstract] [PDF]
|
|
|
|
 |
|
 Minocycline May Improve Outcomes After Acute Stroke Journal Watch (General), October 25, 2007; 2007(1025): 3 - 3. [Full Text]
|
|
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
